ライフサイエンスコーパス: norfloxacin

1 m for enoxacin, 700 nm for ciprofloxacin and norfloxacin).

2 entrations of the fluoroquinolone antibiotic norfloxacin.

3 ifloxacin-to-sarafloxacin, and pefloxacin-to-norfloxacin.

4 presence of a 1 mM concentration gradient of norfloxacin.

5 the DNA gyrase inhibitors coumermycin A1 and norfloxacin.

6 ce and does not survive on medium containing norfloxacin.

7 (2)O(2) similarly oxidizes ciprofloxacin and norfloxacin.

8 the bactericidal antibiotics polymyxin B and norfloxacin.

9 SA growth in combination with the antibiotic norfloxacin.

10 in, 500 mg/d; levofloxacin, 250-500 mg/d; or norfloxacin, 400 mg/d).

11 resistance to two major antibacterial drugs--norfloxacin, a fluoroquinolone, and erythromycin, a macr

12 In this work, we demonstrate that norfloxacin, a model quinolone, converts Escherichia col

13 Furthermore, we showed that portions of norfloxacin accumulated by starved cells were pumped out

14 When associated with norfloxacin against the SA 1199B strain, 4-allyl-2,6-dim

15 in the accumulation of lipophilic molecules (norfloxacin and chenodeoxycholate) and a small increase

16 less rapid influx of two lipophilic agents, norfloxacin and chenodeoxycholate.

17 Norfloxacin and ciprofloxacin - d8 were used as internal

18 s well as a fourfold increase in the MICs of norfloxacin and ciprofloxacin for these two strains.

19 scripts and a 2-fold decrease in the MICs of norfloxacin and ciprofloxacin in strain RN6390.

20 mples detected two prescription antibiotics, norfloxacin and ciprofloxacin, at concentrations of 36 a

21 gococci to the same compounds, as well as to norfloxacin and ciprofloxacin.

22 aphenyl phosphonium and the fluoroquinolones norfloxacin and ciprofloxacin.

23 us NorA efflux pump (EP) in association with norfloxacin and ethidium bromide.

24 NA cleavage was also seen in the presence of norfloxacin and oxolinic acid, two quinolones that are i

25 nt showed a 2-fold increase in resistance to norfloxacin and rhodamine, both substrates of the NorC t

26 r levofloxacin, 2.00 (95% CI, 1.06-3.79) for norfloxacin, and 1.17 (95% CI, .59-2.31) for ofloxacin.

27 ased resistance toward H(2)O(2), vancomycin, norfloxacin, and ciprofloxacin under anaerobic condition

28 ations of gentamicin, tobramycin, ofloxacin, norfloxacin, and ciprofloxacin.

29 ktonic cells more susceptible to tobramycin, norfloxacin, and hydrogen peroxide.

30 ular organic compounds (e.g., propylparaben, norfloxacin, and ofloxacin), thanks to its combined effe

31 The drugs are propranolol, simvastatin, norfloxacin, and warfarin, which in combination would co

32 well as between psorospermin and A-62176 and norfloxacin, are consistent with this model and provide

33 on of seven fluoroquinolones (marbofloxacin, norfloxacin as internal standard, ciprofloxacin, danoflo

34 ger than caliper readings for ciprofloxacin, norfloxacin, aztreonam, erythromycin, clindamycin, and t

35 ty to quinolones and to amphipathic cations (norfloxacin, benzalkonium chloride, cetrimide, pentamidi

36 drug-DNA-enzyme complexes, we show: (i) that norfloxacin binding to DNA induces a structural alterati

37 Norfloxacin blocked decatenation in wild-type strains, b

38 ase IV and gyrase, with potencies similar to norfloxacin but 10-fold lower than newer agents, for exa

39 cumulation level of a hydrophilic quinolone, norfloxacin, by M. smegmatis harboring a plasmid carryin

40 Instead, norfloxacin causes DNA damage, as evidenced by the induc

41 1) for danofloxacin; 0.0050-50 mug L(-1) for norfloxacin, ciprofloxacin and enrofloxacin; and 0.010-5

42 charge state of three different substrates (norfloxacin, ciprofloxacin, and enoxacin) by varying the

43 tocleavage reactions of the fluoroquinolones norfloxacin, ciprofloxacin, and enoxacin.

44 Here, we show that the FQ drugs norfloxacin, ciprofloxacin, and enrofloxacin are powerfu

45 spiked with nine quinolones (marbofloxacin, norfloxacin, ciprofloxacin, danofloxacin, enrofloxacin,

46 neral inhibition of DNA helicases by Topo IV-norfloxacin-DNA ternary complexes did not require the cl

47 ess the effect of topoisomerase IV (Topo IV)-norfloxacin-DNA ternary complexes on the DnaB, T7 gene 4

48 Norfloxacin efflux mediated by LfrA was competed for str

49 s taking fluoroquinolone antibiotics such as norfloxacin exhibit a low incidence of convulsions and a

50 a similar growth inhibition curve to that of norfloxacin in E.coli.

51 umulation of the fluoroquinolone antibiotic, norfloxacin, in proteoliposomes.

52 Quinolone drugs, such as norfloxacin, inhibit the type 2 topoisomerases, DNA gyra

53 t concentration (0.003 mg/ml), ofloxacin and norfloxacin inhibited keratocyte proliferation significa

54 Norfloxacin inhibition of Topo IV induces a slow decline

55 ylactoid reactions induced by ciprofloxacin, norfloxacin, lomefloxacin, moxifloxacin, and baicalin.

56 We estimate a flux of about 10 norfloxacin molecules per second per OmpF trimer in the

57 in fish farming waters is presented, having Norfloxacin (NFX) as target compound.

58 electrode is prepared and applied to detect norfloxacin (NFX) based on its electrochemical reduction

59 ored TT over C-containing sites, more so for norfloxacin (NFX) than acetone, in accord with their dif

60 ign and synthesis of novel Ciprofloxacin and Norfloxacin nitric oxide (NO) photo-donor hybrids to exp

61 Norfloxacin (NOF) is an environmentally harmful and ubiq

62 antibiotics such as ciprofloxacin (CIP) and norfloxacin (NOR) for their quantification in poultry eg

63 gradation rate of sulfamethoxazole (SMX) and norfloxacin (NOR) were 97.4 +/- 2.9% and 96.1 +/- 3.0%,

64 two fluoroquinolones, flumequine (FLU), and norfloxacin (NOR), with goethite (alpha-FeOOH) or mangan

65 We show (i) that Gyr-norfloxacin (Norf)-DNA and Topo IV-Norf-DNA, but not Gyr

66 sarafloxacin (SRFX, IC(50), 0.96 mug L(-1)), norfloxacin (NRFX, IC(50), 0.78 mug L(-1)), ofloxacin (O

67 Furthermore, ciprofloxacin, norfloxacin, ofloxacin, and gatifloxacin exhibited conce

68 Commonly used antibiotics (sulfamethazine, norfloxacin, ofloxacin, tetracycline, and erythromycin)

69 prevent secondary bacterial infection, 0.3% norfloxacin or 0.25 % chloramphenicol were prescribed.

70 l-designed study supported the use of either norfloxacin or amoxicillin-clavulanic acid in the treatm

71 At pH 5, where norfloxacin permeability across pure phospholipid membra

72 fection (hazard ratio [HR], 4.43), long-term norfloxacin prophylaxis (HR, 2.69), recent infection by

73 Norfloxacin prophylaxis resulted in savings between $221

74 e phthalate ester hydrolase, a fragment of a norfloxacin resistance-like transporter, and the convers

75 and 620 nm for enoxacin, ciprofloxacin, and norfloxacin, respectively).

76 responding to two different charge states of norfloxacin that bacteria are likely to encounter in the

77 us to inhibit selectively with the quinolone norfloxacin topo IV, gyrase, both enzymes, or neither en

78 nion activity is required for formation of a norfloxacin-topoisomerase IV-DNA ternary complex that ca

79 have increased sensitivity to low levels of norfloxacin treatment, but the mutations had more pronou

80 de (a substrate for several efflux pumps) or norfloxacin was used as a parameter of EP inhibition.

81 topoisomerase IV, or both, were resistant to norfloxacin, we determined that specific interactions be

82 ndac, ibuprofen, ketoprofen, diclofenac, and norfloxacin) were infused into rats with biliary fistula

83 ics, namely ciprofloxacin, sarafloxacin, and norfloxacin, were found to be equally or more potent tha

84 Modification of norfloxacin yields molecules such as compound 4 that pot